Additionally, the 2 year trial provided not only robust data on semaglutide efficacy, but also safety
In Phase 2 trials (the TRIUMPH-2 study involving 338 participants over 48 weeks), the 12 mg dose of Retatrutide produced an average weight loss of 24.2%
In patients with type two diabetes, Semaglutide GLP-1 (Wegovy, Ozempic , Rybelsus ) reduces blood sugar levels and reduces the risk of major cardiovascular events such as heart attacks and strokes
Your body has a complex signaling system that regulates hunger, blood sugar, fat storage, and energy expenditure
Support for Energy & Fatigue Reduction
The FLOW trial, the first dedicated kidney outcomes trial designed specifically to evaluate a GLP-1 medicine in people with chronic kidney disease and type 2 diabetes, was stopped early because an independent monitoring committee determined that clear evidence of benefit had already emerged.[11] In clinical research, trials are rarely stopped early